• Explore /
  • Videos & Slides
  • / Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.

Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis.

Abstract Video & Slides Poster

Presenter

Sun Young Rha

Sun Young Rha, MD, PhD

Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Videos & Slides Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04888663

DOI

10.1200/JCO.2022.40.4_suppl.330

Abstract #

330

Poster Bd #

K8

Abstract Disclosures

Similar Videos & Slides

Speaker: Sun Young Rha, MD, PhD

Speaker: Filippo Pietrantonio, MD

Speaker: Diego Felipe Ballen, MD

Speaker: Sun Young Rha, MD, PhD